ALDEYRA THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-5.5M | $-3.5M | $-7.7M | $-9.8M | $-9.9M | $-15.1M | $-16.8M | $-8.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $66.6K | — | — | $60.9K | — | — | $60.6K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $-987.6K | — | — | $2.2M | — | — | $1.5M |
| Net Cash from Operating Activities | $-4.6M | $-5.1M | $-7.0M | $-8.6M | $-12.5M | $-8.0M | $-13.2M | $-10.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $0 | — | — | $7.3M | — | — | $-30.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $71.1K | — | — | $1.0M | — | — | $18.2K |
| Net Change in Cash | — | $-5.0M | — | — | $-4.2M | — | — | $-40.3M |
| Free Cash Flow | — | — | — | — | — | — | — | — |